In 2011, the Bohn lab noted antinociception towards both equally chemically induced and inflammation-derived pain, and experiments indicated insufficient opioid receptor modulation, but ended up not able to define a certain focus on. "The discovery of ACKR3 for a target of conolidine even further emphasises the role of this https://whatischronicpain78653.csublogs.com/37557686/about-conolidine